Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for June 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2014.

For an indepth analysis of these deals, read 'Pharma deals during June 2014'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Covidien/ Medtronic
Company acquisition
Medical device company adding US critical mass
42,900
Idenix Pharmaceuticals/ Merck & Co
Company acquisition
Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs
3,850
Labrys Biologics/ Teva
Company acquisition
Includes Labrys' p2b anti-CGRP mAb for treatment of episodic migraine
825
Chelsea Therapeutics/ Lundbeck
Company acquisition
Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved)
658
OAO Veropharm/ Abbott Laboratories
Company acquisition
Russian based manufacturing company
630
DAVA Pharmaceuticals/ Endo International
Company acquisition
Generics business including generic Doxycycline and Cefdinir
575
Bionomics/ Merck & Co
Exclusive research and licence agreement
BNC 375 in Alzheimer's disease (preclinical)
526
Adaptimmune/ GSK
Co-development and  option
TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2)
350
Genia Technologies/ Roche
Company acquisition
Single molecule, semiconductor, DNA sequencing using nanopore technology
350
Medreich/ Meiji Seika
Company acquisition
India-based manufacturing company
290
Cellectis/ Pfizer
Collaboration
Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology targets (platform)
265* +  $28m equity
Dimension Therapeutics/ Bayer
Licence
Gene  therapy for the treatment of haemophilia A (preclinical)
252
Synairgen/ AstraZeneca
Exclusive global licence
SNG 001 inhaled beta interferon (p2)
232
Ligand Pharmaceuticals/ TG Therapeutics
Exclusive global licence
Development, commercialisation of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors (preclinical)208
Pregenen/ bluebird bio
Company acquisition
Gene editing technology platform156
OraSure Technologies/ AbbVie
Co-promotion**
ODM-201, an investigational novel oral androgen receptor inhibitor (p2)75
Orion/ Bayer
Co-development, option to co-promote in Europe
OraQuick HCV rapid test in US
68
Sorrento Therapeutics / Morphotek
Research and option agreement

To generate chemotherapeutic antibody drug conjugates (ADCs) (platform)
50
NanoString Technologies/ Celgene
Development
Development of a companion diagnostic assay
45
ECR Pharmaceuticals / Valeant
Company acquisition
Akorn subsidiary with branded generics business
41

All deals are worldwide unless otherwise noted.
* Deal terms included up to $185m milestones per product; estimated headline could be approximately $2.8bn if all products are successful.
**US only

The Deal Watch table is compiled by Medius Associates

9th July 2014

The Deal Watch table is compiled by Medius Associates

9th July 2014

From: Research, Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Infographics